{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:10:52Z","timestamp":1762521052209},"reference-count":16,"publisher":"Microbiology Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,6,1]]},"abstract":"<jats:p>In this study, the ease of selection of clarithromycin resistance was investigated in clarithromycin-susceptible <jats:italic>Helicobacter pylori<\/jats:italic> strains isolated from patients with <jats:italic>H. pylori<\/jats:italic> infection prior to the administration of triple-combination eradication therapy (clarithromycin plus amoxicillin plus a proton pump inhibitor). Clarithromycin-susceptible strains isolated from ten patients in whom the eradication therapy was successful and from six patients in whom the eradication therapy was unsuccessful were exposed serially to subinhibitory concentrations of clarithromycin. The number of transfers required for the MICs of the strains to increase by 8- and 32-fold were 6.6 and 7.2, respectively, in the successful eradication group, and as few as 2.4 and 1.5, respectively, in the unsuccessful eradication group. The number of transfers required for the A2142G or A2143G point mutation of the 23S rRNA gene to be detected in the strains were 5 and 8, respectively, for the strains in the successful eradication group, and 1 and 2, respectively, for the strains in the unsuccessful eradication group. These results suggest that patients in the unsuccessful eradication group were infected with strains of <jats:italic>H. pylori<\/jats:italic> that readily became resistant to clarithromycin on exposure to the drug.<\/jats:p>","DOI":"10.1099\/jmm.0.46316-0","type":"journal-article","created":{"date-parts":[[2006,5,10]],"date-time":"2006-05-10T18:20:46Z","timestamp":1147285246000},"page":"737-740","source":"Crossref","is-referenced-by-count":19,"title":["Helicobacter pylori isolated from patients who later failed H. pylori eradication triple therapy readily develop resistance to clarithromycin"],"prefix":"10.1099","volume":"55","author":[{"given":"Intetsu","family":"Kobayashi","sequence":"first","affiliation":[{"name":"Chemotherapy Division, Mitsubishi Kagaku Bio-Clinical Laboratories, Inc., 3-30-1 Shimura, Itabashi-ku, Tokyo 174-8555, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Saika","sequence":"additional","affiliation":[{"name":"Chemotherapy Division, Mitsubishi Kagaku Bio-Clinical Laboratories, Inc., 3-30-1 Shimura, Itabashi-ku, Tokyo 174-8555, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroe","family":"Muraoka","sequence":"additional","affiliation":[{"name":"Chemotherapy Division, Mitsubishi Kagaku Bio-Clinical Laboratories, Inc., 3-30-1 Shimura, Itabashi-ku, Tokyo 174-8555, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunari","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Faculty of Medicine, Oita University, Hasama-machi, Oita 879-5593, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Fujioka","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Faculty of Medicine, Oita University, Hasama-machi, Oita 879-5593, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"345","reference":[{"key":"R1","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1128\/JCM.39.4.1319-1322.2001","article-title":"cagA status and eradication treatment outcome of anti- Helicobacter pylori triple therapies in patients with nonulcer dyspepsia","volume":"39","author":"Broutet","year":"2001","journal-title":"J Clin Microbiol"},{"key":"R2","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1046\/j.1365-2036.1999.00549.x","article-title":"Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori : a prospective study of 1-week lansoprazole, amoxicillin and clarithromycin in active peptic ulcer","volume":"13","author":"Duc\u00f3ns","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"R3","first-page":"8","article-title":"European Helicobacter pylori Study Group","volume":"41","year":"(1997","journal-title":"The Maastricht Consensus Report. Gut"},{"key":"R4","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1128\/AAC.46.12.3765-3769.2002","article-title":"New site of modification of 23S rRNA associated with clarithromycin resistance of Helicobacter pylori clinical isolates","volume":"46","author":"Fontana","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"R5","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1128\/AAC.34.9.1637","article-title":"In vitro selection of resistant Helicobacter pylori","volume":"34","author":"Haas","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"R6","first-page":"2","article-title":"Japanese Society for Helicobacter Research","volume":"2","year":"(2000","journal-title":"Jpn J Helicobacter Res"},{"key":"R7","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1046\/j.1523-5378.2003.00145.x","article-title":"Mixed-infection of antibiotic susceptible and resistant Helicobacter pylori isolates in a single patients and underestimation of antimicrobial susceptibility testing","volume":"8","author":"Kim","year":"2003","journal-title":"Helicobacter"},{"key":"R8","first-page":"719","article-title":"Drug susceptibility of Helicobacter pylori freshly isolated from gastrointestinal mucosa of patients with peptic ulcer","volume":"14","author":"Kobayashi","year":"1996","journal-title":"Jpn J Chemother"},{"key":"R9","first-page":"236","article-title":"Relationship between clarithromycin breakpoint for Helicobacter pylori and point mutation in 23S rRNA gene","volume":"46","author":"Kobayashi","year":"2001","journal-title":"Jpn J Chemother"},{"key":"R10","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1365-2036.2002.01368.x","article-title":"Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin","volume":"16","author":"Murakami","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"R11","volume-title":"Performance standards for antimicrobial susceptibility testing . Thirteenth informational supplement M100-S13","year":"2003"},{"key":"R12","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1128\/JCM.37.12.4174-4176.1999","article-title":"Rare incidence of interspousal transmission of Helicobacter pylori in asymptomatic individuals in Japan","volume":"37","author":"Suzuki","year":"1999","journal-title":"J Clin Microbiol"},{"key":"R13","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1128\/AAC.44.8.2118-2125.2000","article-title":"Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage","volume":"44","author":"Tait-Kamradt","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"R14","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1128\/AAC.41.12.2621","article-title":"Cloning and sequence analysis of two copies of a 23S rRNA gene from Helicobacter pylori and association of clarithromycin resistance with 23S rRNA mutations","volume":"41","author":"Taylor","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"R15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1523-5378.1996.tb00003.x","article-title":"Treatment of Helicobacter pylori infection: a review of the world literature","volume":"1","author":"van den Hulst","year":"1996","journal-title":"Helicobacter"},{"key":"R16","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/jac\/40.2.283","article-title":"& 7 other authors","volume":"40","author":"Versalovic","year":"1997","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Medical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jmm\/10.1099\/jmm.0.46316-0?crawler=true","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T04:25:11Z","timestamp":1600835111000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jmm\/10.1099\/jmm.0.46316-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6,1]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,6,1]]}},"URL":"https:\/\/doi.org\/10.1099\/jmm.0.46316-0","relation":{},"ISSN":["0022-2615","1473-5644"],"issn-type":[{"value":"0022-2615","type":"print"},{"value":"1473-5644","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6,1]]}}}